Adding the PARP inhibitor olaparib to neoadjuvant platinum based-chemotherapy was determined to be a safe treatment for patients with triple-negative breast cancer, as well as for patients with breast cancer whose tumors... Read More >>
Overexpression of pro-survival BCL-2 family regulator proteins is an important driver of resistance to cell death in acute myeloid leukemia (AML). Accordingly, the BCL-2 pathway has emerged as an attractive research target for novel therapies.
Data and analysis shared at the 17th International Myeloma Workshop show that anti-BCMA directed treatments, including CAR T-cell therapy, bispecific antibodies, and antibody-drug conjugates have the potential to revolutionize the multiple myeloma treatment paradigm.
Francisco J. Esteva, MD, PhD, director, breast medical oncology program, Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, discusses the future use of biosimilars in breast cancer within the United States. View now